



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/838,028	04/19/2001	Peter Lind	00125US2	3730

26657 7590 09/15/2003

WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP
ATTENTION: SUZANNE E. MILLER ESQ.
ONE LIBERTY PLACE, 46TH FLOOR
PHILADELPHIA, PA 19103

EXAMINER

ULM, JOHN D

ART UNIT	PAPER NUMBER
----------	--------------

1646

DATE MAILED: 09/15/2003

17

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/838,028

Applicant(s)

LIND ET AL.

Examiner

John D. Ulm

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on 25 June 2003.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☐ Claim(s) 1-29,31 and 34-89 is/are pending in the application.
- 4a) Of the above claim(s) 1-29 and 36-81 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) 31,34,35 and 82-89 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

1) Claims 1 to 29, 31 and 34 to 89 are pending in the instant application. Claims 31, 34 and 35 have been amended and claims 82 to 89 have been added as requested by Applicant in the correspondence filed 25 June of 2003.

2) Any objection or rejection of record that is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.

3) The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

4) Claims 1 to 29 and 36 to 81 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 12.

5) Claims 31, 34, 35 and 82 to 89 are rejected under 35 U.S.C. § 101 because they are drawn to an invention with no apparent or disclosed specific and substantial credible utility for those reasons of record as applied to claims 31, 34 and 35 in section 5 of the previous office action. Applicant has traversed this rejection on the premise that a protein of the instant invention has a specific utility in the identification of ligands thereto. As stated in the original rejection, whereas one could readily employ a putative receptor protein of the instant invention in an assay to identify ligands thereto the information obtained thereby would be of little use until one discovers the identity of those physiological processes moderated by that putative receptor. Because the instant specification has failed to credibly identify a physiological process which has been shown to be influenced by the activation or inhibition of a putative receptor protein of the

Art Unit: 1646

instant invention an artisan would have no way of predicting what effects the administration of that ligand to an organism would have. If one can not predict the effects that the administration of a ligand of the putative receptor of the instant invention is going to have on an organism then it is unclear as to what practical benefit is derived by the public from the identification of that ligand.

Applicant has further traversed this rejection on the premise that antibodies to a protein of the instant invention can be used to detect the presence of tissue containing that protein. In essence, Applicant is urging that a protein of the instant invention has utility as a tissue marker. The employment of a protein of the instant invention, or a nucleic acid encoding that protein, as a marker for brain, testis or hypothalamus marker is not a substantial or specific utility. All human proteins can invariably be classified into two categories, those which are expressed in a tissue or developmentally specific manner and those which are expressed ubiquitously. It can be alleged that any protein that is expressed in a tissue specific manner can be employed to detect the tissue in which it is expressed in a sample. Alternately, a human protein that is expressed ubiquitously can be employed to detect the presence of any human tissue in a sample. Such utilities are analogous to the assertion that a particular protein can be employed as a molecular weight marker, which is neither a specific or substantial utility.

One could just as readily argue that any purified compound having a known structure could be employed as an analytical standard in such processes as nuclear magnetic resonance (NMR), infrared spectroscopy (IR), and mass spectroscopy as well as in polyacrylamide gel electrophoresis (PAGE), high performance liquid chromatography (HPLC) and gas chromatography. None of these processes could be practiced without either calibration standards having known molecular structures or, at least, a range of molecular weight markers having known molecular weights. One could further extrapolate upon this premise by asserting that any item having a fixed measurable parameter can be employed to calibrate any machine or process which measures that parameter. For example, any item having a constant mass within an acceptable range can be employed to calibrate a produce scale in a grocery store. The calibration of produce scales is certainly an important function since most states require produce scales to be calibrated and certified. Therefore, to accept Applicant's arguments that any nucleic acid encoding any protein of human origin is useful as a marker would be comparable to conceding that any object of fixed mass has *prima facie* utility as a weight standard, irrespective of any other properties possessed by that object. It was just such applications that the court appeared to be referring to when it expressed the opinion that all chemical compounds are "useful" to the chemical arts when this term is given its broadest interpretation (*Brenner v. Manson*, 148 U.S.P.Q. 689 (Sus. Ct, 1966)). Because the steroid compound which was the subject of that decision had a known structure and molecular weight it could have readily been employed as a molecular standard at that time. Further, because that compound was a

Art Unit: 1646

hydrocarbon it certainly could have been employed in the well known process of combustion for purposes of lighting and/ or the generation of heat. The generation of heat by combustion of hydrocarbons certainly was and remains an important process. Irrespective of such obvious utilities, the court still held that the compound produced by the process at issue in *Brenner v. Manson* did not have a specific and substantial utility.

To grant Applicant a patent encompassing an isolated polynucleotide encoding a naturally occurring human protein of as yet undetermined biological significance would be to grant Applicant a monopoly "the metes and bounds" of which "are not capable of precise delineation". That monopoly "may engross a vast, unknown, and perhaps unknowable area" and "confer power to block off whole areas of scientific development, without compensating benefit to the public" (*Brenner v. Manson, Ibid*). To grant Applicant a patent on the claimed polynucleotide based solely upon an assertion that the protein encoded thereby can be employed as a tissue marker is clearly prohibited by this judicial precedent since the compensation to the public is not commensurate with the monopoly granted and would be no different than granting a patent on the process disputed in *Brenner v. Manson* on the premise that the steroid produced thereby was useful as an analytical standard or as a combustible fuel source.

The disclosure that a protein of the instant invention is expressed predominantly in testicular, hypothalamic and brain tissue does not constitute an assertion of a specific utility. Until one knows just what effects are to be expected from the stimulation or inhibition of a Con-218 protein of the instant invention, one can not use that protein in a specific manner from which the public receives an immediate benefit. Whereas one

Art Unit: 1646

would certainly conclude that Con-218 plays some physiological role in testicular, hypothalamic and brain function, it lacks immediate utility in the absence of the knowledge of what role it plays in that tissue or in some disease process associated with that tissue.

Applicant has traversed this rejection of the premise that it is in conflict with the "REVISED INTERIM UTILITY GUIDELINES TRAINING MATERIALS" (<http://ptoweb.uspto.gov/patents/filecab/documents/Utility.pdf> - 188.0KB, 28 Feb. 2000). A proper analysis of the instant claims, which are drawn to an isolated orphan receptor, should be made in light of Example 12 of those guidelines, which explains why an isolated "orphan receptor" lacks utility in the absence of the disclosure of a specific role for either the nucleic acid or protein in a known disease or disorder or a physiological process which one would wish to manipulate for clinical effect.

6) Claims 31, 34, 35 and 82 to 89 are rejected under 35 U.S.C. § 112, first paragraph, as failing to adequately teach how to use the instant invention for those reasons given above with regard to the rejection of these claims under 35 U.S.C. § 101. Applicant has traversed this rejection on the premise that it has not been fully developed. Applicant's attention is directed to M.P.E.P. 2107 II B (2), which states:

"If no assertion of specific and substantial utility for the claimed invention made by the applicant is credible, and the claimed invention does not have a readily apparent well-established utility, reject the claim(s) under 35 U.S.C. 101 on the grounds that the invention as claimed lacks utility. Also reject the claims under 35 U.S.C. 112, first paragraph, on the basis that the disclosure fails to teach how to use the invention as claimed. The 35 U.S.C. 112, first paragraph, rejection imposed in conjunction with a

Art Unit: 1646

35 U.S.C. 101 rejection **should incorporate by reference the grounds of the corresponding 35 U.S.C. 101 rejection.**"

Emphasis added. The basis for rejecting the instant claims under 35 U.S.C. § 112, first paragraph, was fully developed in the rejection of these claims for lack of utility under 35 U.S.C. § 101.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7) Claims 87 to 89 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. These claims are vague and indefinite because the limitation "stringent hybridization conditions" is conditional and a single defining set of conditions is not recited in either the claims or the instant specification. The text on page 13 of the instant specification discusses this limitation but defines it in terms of "typical" conditions rather than the specific conditions needed to define such a term.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

8) Claims 30, 35 and 82 to 86 are rejected under 35 U.S.C. 102(b) as being anticipated by the Dohlman et al. publication (Biochemistry 27(6):1813-1817, 1988), for example. These claims encompass any isolated G protein-coupled receptor whose

Art Unit: 1646

amino acid sequence "comprises" a "fragment" of the amino acid sequence presented in SEQ ID NO:2 or SEQ ID NO:4 of the instant application. Because a "fragment" of an amino acid sequence can consist of nothing more than a single amino acid residue and all twenty encodable amino acids are present in each of in SEQ ID NO:2 and SEQ ID NO:4, these claims encompass any isolated G protein-coupled receptor. The Dohlman et al. publication described an isolated hamster adrenergic receptor which meets all of the limitations of the instant claims more than one year before the filing of the instant application.

9) Claims 31, 34, 35 and 82 to 89 are 31, 34 and 35 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by the Gan et al. patent publication (US 2002/0100067 A1) for those reasons of record as applied to claims 31, 34 and 35 is section 7 of the previous office action. As stated therein, Gan et al. provided a written description of the claimed protein. Contrary to Applicant's assertion, the rationale for denying priority was fully explained in the original rejection. Because the prior specification did not disclose a specific and substantial utility for the claimed invention, it did not meet the "how to use" requirement of 35 U.S.C. 112, first paragraph, and, therefore the instant application can not receive benefit from that earlier application under 35 U.S.C. 119(e).

10) Applicant's arguments filed 25 June of 2003 have been fully considered but they are not persuasive for those reasons given above

11) This application contains claim 1 to 29 and 36 to 81, drawn to an invention nonelected with traverse in Paper No.12. A complete reply to the final rejection must

Art Unit: 1646

include cancellation of nonelected claims or other appropriate action (37 CFR 1.144)

See MPEP § 821.01.

12) Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (703) 308-4008. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached at (703) 308-6564.

Official papers filed by fax should be directed to (703) 308-4242 or (703) 872-9306. Official responses under 37 C.F.R. § 1.116 should be directed to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.



JOHN ULM
PRIMARY EXAMINER
GROUP 1800